Peginesatide (trade name Omontys, formerly Hematide), developed by Affymax and Takeda, is an erythropoietic agent, a functional analog of erythropoietin. It was approved by the U.S. Food and Drug Administration for treatment of anemia associated with chronic kidney disease (CKD) in adult patients on dialysis. Peginesatide is a synthetic peptide, attached to polyethylene glycol ("PEGylated"). It mimics the structure of erythropoietin, the human glycoprotein which promotes red blood cell development. Peginesatide binds to and activates the human erythropoietin receptor and stimulates erythropoiesis in human red cell precursors in vitro.
CNS Activity
Originator
Approval Year
PubMed
Patents
Sample Use Guides
Initiate OMONTYS treatment when the hemoglobin level is less than 10 g/dL. The recommended starting dose for the treatment of anemia in patients who are not currently
treated with an ESA is 0.04 mg/kg body weight administered as a single intravenous or subcutaneous injection once monthly.
Route of Administration:
Intravenous
Subunit 0
Subunit 1
| Linkage Type | Residue Index | |
|---|---|---|
| AMIDE BOND | 1_21 | 2_21 |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| MOL_WEIGHT:SEQUENCE(CALCULATED) | CHEMICAL |
SEQUENCE
5204 DA (average) |
||||
| Molecular Formula | CHEMICAL |
ESTIMATED
C196H302N46O56S6 |